-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The financial report for the first quarter of 2022 released by Swiss pharmaceutical giant Novartis (NYSE: NVS) shows that the company's net sales increased by 5% year-on-year (calculated at constant exchange rates, the same below) to $12.
5% Innovative Medicines Sector Sandoz
Source: Novartis Financial Report
The main drivers ofNovartis' innovative business in the quarter were: heart failure drug Nuxinto (sacubitril/valsartan sodium) grew by 42%, and quarterly sales exceeded $1 billion for the first time; autoimmune disease drug Cantilever (secukinumab) up 12%; spinal muscular atrophy drug Zolgensma (Onasemonogene abeparvovec) up 18%; allergic asthma drug Zole (omalizumab) up 17%; breast cancer drug ribociclib ( ribociclib) grew 28%; the recently launched multiple sclerosis drug ofatumumab contributed $195 million
Key drivers of innovative business
Source: Novartis Financial Report
Sales at Novartis ' Innovative Medicines segment rose 3 percent to $3.
Innovative Medicines Sector
Source: Novartis Financial Report
Innocento health insurance takes effect, boosting performance in the Chinese market
Innocento health insurance takes effect, boosting performance in the Chinese marketElsewhere, Novartis' emerging markets, including China, were particularly strong , with 12% growth
Emerging markets performed particularly strongly
The reasons include the inclusion of the new indications of Nuoxinto for essential hypertension into the medical insurance from January, and the strong performance of Cosentyx in China
Nuoxintoxanthin _
Source: Novartis Financial Report
Novartis' recent R&D progress includes the approval of Zhuole for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents (12 years and older) who still have symptoms after taking antihistamines, becoming the only biological drug for this indication in China.
Zoloft Filafinitor _
